3-chloro-5-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;
3-chloro-5-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(difluoromethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;
3-chloro-5-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(1,1-difluoroethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)-5-(difluoromethyl)benzonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(1,1-difluoroethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)-5-(difluoromethyl)benzonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;
5-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(1,1-difluoroethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)isophthalonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(1,1-difluoroethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)-5-fluorobenzonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)-5-fluorobenzonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(1,1-difluoroethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile;
5-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)isophthalonitrile;
3-((1-((6-chloro-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-4-(difluoromethyl)-6-oxo-1,6-dihydropyrimidin-5-yl)oxy)-5-(difluoromethyl)benzonitrile;
3-((1-((6-bromo-3-oxo-2,3-dihydropyridazin-4-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrilel;
or a pharmaceutically acceptable salt of any of the foregoing compounds.

20. A pharmaceutical composition comprising an effective amount of the compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. Use of the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ~~A method for~~ the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof, ~~which comprises administering to the subject an effective amount of the~~

~~compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.~~


22. The ~~method~~ use of claim 21, further comprising ~~administering to the subject~~ one or more ~~a second~~ HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

23. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

24. Use of a compound according to any one of claims 1 to 19 in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

25. The pharmaceutical composition of claim 20 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

26. The compound



or a pharmaceutically acceptable salt thereof.


27. A pharmaceutical composition comprising an effective amount of the compound according to claim 26, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

28. The pharmaceutical composition of claim 27 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

29. Use of the compound according to claim 26, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

30. The use of claim 29 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

31. The compound



or a pharmaceutically acceptable salt thereof.


32. A pharmaceutical composition comprising an effective amount of the compound according to claim 31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

33. The pharmaceutical composition of claim 32 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

34. Use of the compound according to claim 31, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

35. The use of claim 34 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

36. The compound



or a pharmaceutically acceptable salt thereof.


37. A pharmaceutical composition comprising an effective amount of the compound according to claim 36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

38. The pharmaceutical composition of claim 37 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

39. Use of the compound according to claim 36, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

40. The method of claim 39 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

41. The compound



or a pharmaceutically acceptable salt thereof.


42. A pharmaceutical composition comprising an effective amount of the compound according to claim 41, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

43. The pharmaceutical composition of claim 42 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

44. Use of the compound according to claim 41, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

45. The use of claim 44 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

46. The compound



or a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition comprising an effective amount of the compound according to claim 46, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

48. The pharmaceutical composition of claim 47 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

49. Use of the compound according to claim 46, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylaxis or treatment of infection by HIV or for the prophylaxis, treatment, or delay in the onset of AIDS in a subject in need thereof.

50. The use of claim 49 further comprising one or more HIV antiviral agent selected from the group consisting of HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, and HIV entry inhibitors.

51. The pharmaceutical composition according to any one of claims 25, 28, 33, 38, 43 or 48, wherein the one or more anti-HIV agent is one or more HIV antiviral selected from:

abacavir, abacavir sulfate,
abacavir +lamivudine,
abacavir + lamivudine + zidovudine,
amprenavir,
atazanavir, atazanavir sulfate,
zidovudine,
capravirine
darunavir,
zalcitabine,
didanosine,
enteric coated didanosine
delavirdine,
efavirenz,
efavirenz + emtricitabine + tenofovir disoproxil fumarate,
EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine)

emtricitabine,
emtricitabine + tenofovir disoproxil fumarate,
emvirine,
enfuvirtide,
etravirine,
fosamprenavir calcium,
indinavir, indinavir sulfate,
lamivudine,
lamivudine + zidovudine,
lopinavir,
lopinavir + ritonavir,
maraviroc,
nelfinavir, nelfinavir mesylate,
nevirapine,
PPL-100,
raltegravir,
ritonavir,
saquinavir, saquinavir mesylate,
stavudine,
tenofovir disoproxil fumarate,
tenofovir hexadecyloxypropyl,
tipranavir.

52. The use according to any one of claims 22, 30, 35, 40, 45 or 50, wherein wherein the one or more anti-HIV agent is one or more HIV antiviral selected from:

abacavir, abacavir sulfate,
abacavir +lamivudine,
abacavir + lamivudine + zidovudine,
amprenavir,
atazanavir, atazanavir sulfate,
zidovudine,
capravirine
darunavir,
zalcitabine,
didanosine,

enteric coated didanosine
delavirdine,
efavirenz,
efavirenz + emtricitabine + tenofovir disoproxil fumarate,
EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine)
emtricitabine,
emtricitabine + tenofovir disoproxil fumarate,
emvirine,
enfuvirtide,
etravirine,
fosamprenavir calcium,
indinavir, indinavir sulfate,
lamivudine,
lamivudine + zidovudine,
lopinavir,
lopinavir + ritonavir,
maraviroc,
nelfinavir, nelfinavir mesylate,
nevirapine,
PPL-100,
raltegravir,
ritonavir,
saquinavir, saquinavir mesylate,
stavudine,
tenofovir disoproxil fumarate,
tenofovir hexadecyloxypropyl,
tipranavir,